

When it comes to advancing therapies for brain disorders, we stand apart. Here's how:

No other global company is focused solely on the brain

- We have one purpose: to improve the quality of life for those affected by psychiatric and neurological disorders
- While others are retreating from brain research, we are fully committed – the unmet needs in psychiatric and neurological disorders are too great to back down

70+ years of experience

in brain disorder research and treatment

And we're just getting started



We are foundation owned

The Lundbeck Foundation owns 70% of our company, binding our corporate purpose to neuroscience research

Meet our largest shareholder:



The Lundbeck Foundation is dedicated to advancing biomedical sciences research, focused primarily on brain research

\$100M

in contributions to research every year

€1M

to annually fund The Brain Prize, the world's largest brain research prize

The brain poses countless questions, we are advancing many solutions

Lundbeck dedicates **100%** of our R&D efforts to developing innovative therapies for brain disorders

We invest **20%** of global revenues into R&D in our four areas of focus:



Therapeutic areas of research focus:

ALZHEIMER'S DISEASE

DEPRESSION

PARKINSON'S DISEASE

SCHIZOPHRENIA

In our pipeline:

- mid- to late-stage symptomatic treatments
- early-stage disease-modifying projects



We stand shoulder-to-shoulder with our communities

- **DOZENS** of strategic relationships with leading public, private and academic partners
- We **SHOW UP** for our communities, and employees participate in **HUNDREDS** of patient events each year

We've heard it from those we serve

RANKED FIRST in corporate reputation by U.S. patient groups for three straight years

Source: PatientView "Corporate Reputation of Pharma"



ABOUT LUNDBECK

1915: Founded in Copenhagen, Denmark

2009: Established U.S. Headquarters in Deerfield, IL

5,200 Global Employees

900 U.S. Employees